Short- and long-term outcomes after perioperative EOX therapy versus upfront surgery for gastric cancer: a single-centre propensity score–matched cohort study
Abstract Introduction Despite radical surgery, gastric cancer (GC) survival rates remain low in Western countries. Randomised trials suggest that perioperative chemotherapy downstages disease, improving long-term survival without increasing complications. We compared outcomes for upfront surgery (US...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Surgery |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12893-025-02919-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849314670770388992 |
|---|---|
| author | Johan Back Ville Sallinen Akseli Bonsdorff Arto Kokkola Pauli Puolakkainen |
| author_facet | Johan Back Ville Sallinen Akseli Bonsdorff Arto Kokkola Pauli Puolakkainen |
| author_sort | Johan Back |
| collection | DOAJ |
| description | Abstract Introduction Despite radical surgery, gastric cancer (GC) survival rates remain low in Western countries. Randomised trials suggest that perioperative chemotherapy downstages disease, improving long-term survival without increasing complications. We compared outcomes for upfront surgery (US) versus surgery combined with perioperative EOX (epirubicin, oxaliplatin, capecitabine) therapy for short- and long-term survival. Methods We analysed 310 patients who underwent curative intent gastrectomy for GC at a single tertiary centre from 2006 to 2017. Patients were assigned to the EOX group (n = 105) or the US group (n = 205). Propensity score matching (PSM) was utilised to balance baseline characteristics, clinical stage, surgery type, and histology. Short-term outcomes included the Comprehensive Complication Index (CCI) and 30-day mortality, while long-term outcomes were overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS). Results After PSM, 102 patients remained in each group. The EOX group exhibited significantly lower preoperative haemoglobin levels compared to the US group, but other baseline characteristics were comparable. Tumour-related outcomes favoured the EOX group, with significantly smaller tumours (P < 0.001), fewer metastatic lymph nodes (P = 0.004), and lower tumour stages overall. Splenectomy was more common in the US group (40.2% versus 23.5%, P = 0.011). Postoperative complications were similar between groups, although ICU admissions were more frequent in the EOX group (16.7% versus 6.9%, P = 0.030). Thirty-day mortality rates were low and comparable (1.0% in the EOX group versus 2.0% in the US group, P = 1.000). Long-term outcomes, including overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS), showed no significant differences between the groups. Conclusions Perioperative EOX therapy is as safe as upfront surgery and significantly reduces metastatic lymph nodes and tumour size, suggesting its role in downstaging the disease. However, despite these promising oncological responses, this benefit does not translate into improved long-term survival. |
| format | Article |
| id | doaj-art-bd0359a8f0f944ffb2ad03640c4386cb |
| institution | Kabale University |
| issn | 1471-2482 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Surgery |
| spelling | doaj-art-bd0359a8f0f944ffb2ad03640c4386cb2025-08-20T03:52:24ZengBMCBMC Surgery1471-24822025-04-0125111310.1186/s12893-025-02919-4Short- and long-term outcomes after perioperative EOX therapy versus upfront surgery for gastric cancer: a single-centre propensity score–matched cohort studyJohan Back0Ville Sallinen1Akseli Bonsdorff2Arto Kokkola3Pauli Puolakkainen4Department of Abdominal Surgery, Helsinki University Hospital and University of Helsinki, Meilahti Tower HospitalDepartment of Abdominal Surgery, Helsinki University Hospital and University of Helsinki, Meilahti Tower HospitalDepartment of Abdominal Surgery, Helsinki University Hospital and University of Helsinki, Meilahti Tower HospitalDepartment of Abdominal Surgery, Helsinki University Hospital and University of Helsinki, Meilahti Tower HospitalDepartment of Abdominal Surgery, Helsinki University Hospital and University of Helsinki, Meilahti Tower HospitalAbstract Introduction Despite radical surgery, gastric cancer (GC) survival rates remain low in Western countries. Randomised trials suggest that perioperative chemotherapy downstages disease, improving long-term survival without increasing complications. We compared outcomes for upfront surgery (US) versus surgery combined with perioperative EOX (epirubicin, oxaliplatin, capecitabine) therapy for short- and long-term survival. Methods We analysed 310 patients who underwent curative intent gastrectomy for GC at a single tertiary centre from 2006 to 2017. Patients were assigned to the EOX group (n = 105) or the US group (n = 205). Propensity score matching (PSM) was utilised to balance baseline characteristics, clinical stage, surgery type, and histology. Short-term outcomes included the Comprehensive Complication Index (CCI) and 30-day mortality, while long-term outcomes were overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS). Results After PSM, 102 patients remained in each group. The EOX group exhibited significantly lower preoperative haemoglobin levels compared to the US group, but other baseline characteristics were comparable. Tumour-related outcomes favoured the EOX group, with significantly smaller tumours (P < 0.001), fewer metastatic lymph nodes (P = 0.004), and lower tumour stages overall. Splenectomy was more common in the US group (40.2% versus 23.5%, P = 0.011). Postoperative complications were similar between groups, although ICU admissions were more frequent in the EOX group (16.7% versus 6.9%, P = 0.030). Thirty-day mortality rates were low and comparable (1.0% in the EOX group versus 2.0% in the US group, P = 1.000). Long-term outcomes, including overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS), showed no significant differences between the groups. Conclusions Perioperative EOX therapy is as safe as upfront surgery and significantly reduces metastatic lymph nodes and tumour size, suggesting its role in downstaging the disease. However, despite these promising oncological responses, this benefit does not translate into improved long-term survival.https://doi.org/10.1186/s12893-025-02919-4Perioperative chemotherapyEOXComplicationsGastric cancer |
| spellingShingle | Johan Back Ville Sallinen Akseli Bonsdorff Arto Kokkola Pauli Puolakkainen Short- and long-term outcomes after perioperative EOX therapy versus upfront surgery for gastric cancer: a single-centre propensity score–matched cohort study BMC Surgery Perioperative chemotherapy EOX Complications Gastric cancer |
| title | Short- and long-term outcomes after perioperative EOX therapy versus upfront surgery for gastric cancer: a single-centre propensity score–matched cohort study |
| title_full | Short- and long-term outcomes after perioperative EOX therapy versus upfront surgery for gastric cancer: a single-centre propensity score–matched cohort study |
| title_fullStr | Short- and long-term outcomes after perioperative EOX therapy versus upfront surgery for gastric cancer: a single-centre propensity score–matched cohort study |
| title_full_unstemmed | Short- and long-term outcomes after perioperative EOX therapy versus upfront surgery for gastric cancer: a single-centre propensity score–matched cohort study |
| title_short | Short- and long-term outcomes after perioperative EOX therapy versus upfront surgery for gastric cancer: a single-centre propensity score–matched cohort study |
| title_sort | short and long term outcomes after perioperative eox therapy versus upfront surgery for gastric cancer a single centre propensity score matched cohort study |
| topic | Perioperative chemotherapy EOX Complications Gastric cancer |
| url | https://doi.org/10.1186/s12893-025-02919-4 |
| work_keys_str_mv | AT johanback shortandlongtermoutcomesafterperioperativeeoxtherapyversusupfrontsurgeryforgastriccancerasinglecentrepropensityscorematchedcohortstudy AT villesallinen shortandlongtermoutcomesafterperioperativeeoxtherapyversusupfrontsurgeryforgastriccancerasinglecentrepropensityscorematchedcohortstudy AT akselibonsdorff shortandlongtermoutcomesafterperioperativeeoxtherapyversusupfrontsurgeryforgastriccancerasinglecentrepropensityscorematchedcohortstudy AT artokokkola shortandlongtermoutcomesafterperioperativeeoxtherapyversusupfrontsurgeryforgastriccancerasinglecentrepropensityscorematchedcohortstudy AT paulipuolakkainen shortandlongtermoutcomesafterperioperativeeoxtherapyversusupfrontsurgeryforgastriccancerasinglecentrepropensityscorematchedcohortstudy |